Rhett Wilkerson: Financial Toxicity in Cancer Care

Rhett Wilkerson, associate director of patient financial services, Florida Cancer Specialists, discusses financial toxicity in cancer care.
November 11, 2019



Transcript

So that is something that, as deductibles and out-of-pockets continue to rise, is something that is prevalent. Being able to be aggressive about reaching out finding copay assistance or foundations or grants that are appropriate for the patient is one way that, you know, we work to alleviate that.

But then also, again, knowing those drug costs and being able to put together successful payment plans that cover, you know, the cost of the drug, and kind of looking at the whole episode of care to really make an aggressive payment plan that fits, that's something that the patient can make and then also covers the cost of the drug.
 

x-button

Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2019 Intellisphere, LLC. All Rights Reserved.